Product news

Share this article:
AstraZeneca submitted applications in the European Union for once-daily Seroquel XR (quetiapine fumarate), seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. This follows two supplemental new drug applications to the FDA announced in January, for the same indications.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions